Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Calithera Biosciences Inc is a biotechnology business based in the US. Calithera Biosciences shares (CALA) are listed on the NASDAQ and all prices are listed in US Dollars. Calithera Biosciences employs 92 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$1.93|
|52-week range||$1.78 - $5.96|
|50-day moving average||$2.19|
|200-day moving average||$2.17|
|Wall St. target price||$5.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.11|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-13)||-6.31%|
|1 month (2021-09-20)||-11.47%|
|3 months (2021-07-20)||-7.21%|
|6 months (2021-04-20)||-5.85%|
|1 year (2020-10-20)||-48.67%|
|2 years (2019-10-18)||-28.25%|
|3 years (2018-10-19)||5.21|
|5 years (2016-10-20)||3|
|Revenue TTM||$3 million|
|Gross profit TTM||$-71,015,000|
|Return on assets TTM||-37.79%|
|Return on equity TTM||-70.71%|
|Market capitalisation||$151.2 million|
TTM: trailing 12 months
There are currently 1.8 million Calithera Biosciences shares held short by investors – that's known as Calithera Biosciences's "short interest". This figure is 7.3% up from 1.6 million last month.
There are a few different ways that this level of interest in shorting Calithera Biosciences shares can be evaluated.
Calithera Biosciences's "short interest ratio" (SIR) is the quantity of Calithera Biosciences shares currently shorted divided by the average quantity of Calithera Biosciences shares traded daily (recently around 551529.375). Calithera Biosciences's SIR currently stands at 3.2. In other words for every 100,000 Calithera Biosciences shares traded daily on the market, roughly 3200 shares are currently held short.
However Calithera Biosciences's short interest can also be evaluated against the total number of Calithera Biosciences shares, or, against the total number of tradable Calithera Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Calithera Biosciences's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Calithera Biosciences shares in existence, roughly 20 shares are currently held short) or 0.0285% of the tradable shares (for every 100,000 tradable Calithera Biosciences shares, roughly 29 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Calithera Biosciences.
Find out more about how you can short Calithera Biosciences stock.
We're not expecting Calithera Biosciences to pay a dividend over the next 12 months.
Calithera Biosciences's shares were split on a 1:48 basis on 18 September 2014. So if you had owned 48 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Calithera Biosciences shares – just the quantity. However, indirectly, the new 4700% higher share price could have impacted the market appetite for Calithera Biosciences shares which in turn could have impacted Calithera Biosciences's share price.
Over the last 12 months, Calithera Biosciences's shares have ranged in value from as little as $1.78 up to $5.96. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Calithera Biosciences's is 1.6968. This would suggest that Calithera Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Calithera Biosciences, Inc. , a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors. The company also offers INCB001158, an oral inhibitor of arginase that is in Phase I/II clinical trial for the treatment of hematology and oncology. The company is also developing CB-280, an oral arginase inhibitor that is in Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and CB-708, an orally administered small molecule inhibitor of CD73, as well as CB-668, an inhibitor of the enzyme IL4I1. It has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.